Abstract: Disclosed are compounds having the formula: wherein R1, R2, R3 and Z are as defined herein, and methods of making and using the same.
Type:
Grant
Filed:
November 14, 2017
Date of Patent:
March 5, 2019
Assignee:
GlaxoSmithKline Intellectual Property Development Limited
Inventors:
Michael Jonathan Bury, Linda N. Casillas, Adam Kenneth Charnley, Pamela A. Haile, Robert W. Marquis, Jr., John F. Mehlmann, Joseph J. Romano, Robert R. Singhaus, Jr., Gren Z. Wang
Abstract: The present invention relates to compositions comprising Haemophilus influenzae Protein E and Pilin A. More particularly, the present application relates to fusion proteins and immunogenic compositions comprising Protein E and PilA, vaccines comprising such immunogenic compositions and therapeutic uses of the same.
Type:
Grant
Filed:
June 30, 2016
Date of Patent:
February 26, 2019
Assignee:
GlaxoSmithKline Biologicals SA
Inventors:
Normand Blais, Steve Labbe, Jan Poolman
Abstract: Apparatus for detecting cracks in optically transparent articles e.g vials, comprising a mount for the article, a light source to direct light at a mounted article, an optical detector positioned to receive light from the light source passed through the article and to generate an electronic signal responsive to received light, first and second (analyzer) polarizers such that light from the light source passes through the first polarizer then through the article, then through the second polarizer on its path to the optical detector, with an optical wave plate positioned between the mount and the second polarizer, and an image processing system to process the electronic signal generated by the optical detector and to indicate the presence or absence of a crack in the article supported on the mount. A method of crack detection using the apparatus is also provided.
Abstract: Compounds of formula (I) and salts thereof: wherein R1 is hydrogen, methyl or —(CH2)2OR3, R2 is methyl or —(CH2)2OR4, or R1 and R2, together with the nitrogen atom to which they are attached, are linked to form a 5- or 6-membered heterocyclyl wherein the 6-membered heterocyclyl is optionally substituted by two hydroxy substituents; R3 and R4 are each independently hydrogen or methyl; and n is an integer having a value of 5 or 6, are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment or prevention of various disorders, for example the treatment or prevention of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants.
Abstract: This invention relates to non-steroidal compounds that are modulators of androgen receptor, and also to the methods for the making and use of such compounds.
Type:
Grant
Filed:
November 22, 2016
Date of Patent:
February 5, 2019
Assignee:
GlaxoSmithKline Intellectual Property (No 2) Limited
Inventors:
Philip Stewart Turnbull, Rodolfo Cadilla
Abstract: Disclosed are compounds having the formula: wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, and R17, are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.
Type:
Grant
Filed:
January 3, 2018
Date of Patent:
January 29, 2019
Assignee:
GlaxoSmithKline Intellectual Property Development Limited
Abstract: This invention relates to methods for the preparation of a compound which is an inhibitor of acyl coenzyme A: diacylglycerol acyltransferase 1 (DGAT-1).
Abstract: Aspects of the present invention are directed to a metered dose container. The container may comprise a body; a first barrier in contact with a base of the container and extending partially along the vertical axis of the body; a second barrier in contact with a top of the container and extending partially along with vertical axis of the body. The space between the first barrier and the second barrier preferably defines a loading chamber, the space between the second barrier and a front wall of the container preferably defines a dispensing chamber, and the space between a rear wall of the container and the first barrier preferably defines a storage chamber. The base preferably also comprises a depressible portion that can convert the container from a transit mode to a dispensing mode.
Abstract: The present invention relates to LpxC antibacterial compounds of Formula (IA): corresponding pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, compound preparation, treatment methods and uses for bacterial infections, especially those caused by gram-negative bacteria.
Type:
Application
Filed:
December 8, 2016
Publication date:
December 20, 2018
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Inventors:
Qi JIN, Denise Teotico POHLHAUS, Jared T. SPLETSTOSER
Abstract: The invention relates to bacterial mutants, particularly from Streptococcus agalactiae, that secrete capsular polysaccharide and methods of purifying the secreted bacterial capsular polysaccharides from culture medium. The extracted polysaccharides are useful for producing vaccines comprising the polysaccharides alone or conjugated to proteins.
Type:
Grant
Filed:
May 5, 2015
Date of Patent:
December 11, 2018
Assignee:
GlaxoSmithKline Biologicals SA
Inventors:
Evita Balducci, Francesco Berti, Valdemar Robert Janulczyk, Immaculada Margarit Y Ros, Chiara Toniolo
Abstract: A compound of formula (I) or a salt thereof: wherein R1 represents a five-membered aromatic heterocycle selected from a N- or a C-linked mono- or di-substituted pyrazole, an N- or a C-linked optionally mono- or di-substituted triazole or an N- or a C-linked optionally mono- or di-substituted imidazole, which five-membered aromatic heterocycle may be substituted by one or two of the groups selected a methyl group, an ethyl group, a fluorine atom, a hydroxymethyl group, a 2-hydroxypropan-2-yl group, a trifluoromethyl group, a difluoromethyl group or a fluoromethyl group, except that when R1 represents an N-linked mono- or di-substituted pyrazole, R1 does not represent 3,5-Dimethyl-1H-pyrazol-1-yl, 5-Methyl-1H-pyrazol-1-yl, 5-Ethyl-3-methyl-1H-pyrazol-1-yl, 3,5-Diethyl-1H-pyrazol-1-yl, 4-Fluoro-3,5-dimethyl-1H-pyrazol-1-yl, 3-Methyl-1H-pyrazol-1-yl or 1H-pyrazol-1-yl.
Type:
Grant
Filed:
September 22, 2015
Date of Patent:
December 4, 2018
Assignee:
GlaxoSmithKline Intellectual Property Development Limited
Inventors:
Niall Andrew Anderson, Ian Baxter Campbell, Matthew Howard James Campbell-Crawford, Ashley Paul Hancock, Seble Lemma, Simon John Fawcett MacDonald, John Martin Pritchard, Panayiotis Alexandrou Procopiou
Abstract: The present invention generally relates to compositions comprising benzonapthyridine small molecule immune potentiators (SMIPs) that are capable of stimulating or modulating an immune response in a subject that has had pre- or post-exposure to a pathogen such as hemorrhagic fever virus. Also provided are methods of preparing and using the SMIP compositions of the invention.
Type:
Application
Filed:
February 9, 2017
Publication date:
November 22, 2018
Applicants:
GlaxoSmithKline Biologicals SA, U.S. Army Medical Research and Materiel Command
Inventors:
Gillis OTTEN, Tom Yao-Hsiang WU, Travis K. WARREN, Sina BAVARI
Abstract: The invention provides a process for the reductive amination of a carbonyl group at the reducing terminus of a polysaccharide, wherein the reductive amination is carried out at a pH between 4 and 5. The invention also provides a process for preparing a conjugate of a polysaccharide and a carrier molecule, comprising the steps of: (a) coupling the polysaccharide to a linker, to form a polysaccharide-linker compound in which the free terminus of the linker is an ester group; and (b) reacting the ester group with a primary amine group in the carrier molecule, to form a polysaccharide-linker-carrier molecule conjugate in which the linker is coupled to the carrier molecule via an amide linkage. The invention also provides a process for reducing contamination of a polysaccharide-linker compound with unreacted linker, comprising a step of precipitating unreacted linker under aqueous conditions at a pH of less than 5.
Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.
Type:
Grant
Filed:
July 21, 2015
Date of Patent:
November 13, 2018
Assignee:
GlaxoSmithKline Intellectual Property Development Limited
Inventors:
Zehong Wan, Xiaomin Zhang, Jian Wang, Matthew Robert Sender, Eric Steven Manas, Raphael Anthony Rivero, Joseph E Pero, Christopher Ernst Neipp, Vipulkumar Kantibhai Patel